Filing Flows › Opus Genetics (IRD) › Q2 2025
Opus Genetics (IRD) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Opus Genetics (IRD) reported revenue of $2.9M for the second quarter 2025 (Q2 2025), +159% from a year earlier and -34% from the quarter before. Operating margin was -309.0%, net loss $7.4M (257.5% of revenue).
Opus Genetics, Q2 2025: revenue $2.9M (+159% year over year), operating margin -309.0%, net loss $7.4M, operating cash flow −$10.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.9M | -34% | +159% |
| Operating profit | −$8.9M | — | — |
| Net earnings | −$7.4M | — | — |
| Operating cash flow | −$10.3M | — | — |
What changed
Revenue was $2.9M in Q2 2025, up 159% year over year and down 34% from the previous quarter.
Operating costs exceeded revenue by $8.9M, an operating margin of -309.0%. Total costs grew 25% against revenue growth of 159%. The fastest-growing cost line was General & admin (+72%). The quarter ended with a net loss of $7.4M, narrower than the previous quarter's $8.2M loss. Non-operating items added $1.5M, -20% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$10.3M. Non-cash charges added back $14K of depreciation and $896K of share-based compensation. Working capital and other items used $3.8M.
Questions
What was Opus Genetics' revenue in the second quarter 2025?
Opus Genetics (IRD) reported revenue of $2.9M for the second quarter 2025 (Q2 2025), +159% from a year earlier and -34% from the quarter before.
Was Opus Genetics profitable in the second quarter 2025?
Operating loss was $8.9M (-309.0% of revenue) and net loss $7.4M.
Source: Opus Genetics 10-Q on SEC EDGAR.